HALF PRICE OFFER ENDS TODAY! New Elbow X-ray Interpretation Course by Andrew Murphy REGISTER NOW

Angioimmunoblastic T cell lymphoma

Angioimmunoblastic T-cell lymphoma (AITL) (previously known as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)) is a rare, aggressive (fast-growing) form of peripheral T-cell lymphoma. It only accounts for around 1-2% of all non-Hodgkin lymphoma. It is one of the more common subtypes of mature T-cell lymphomas. 

It is more common in the elderly.

The clinical spectrum includes:

Despite advances in treatment regimens for angioimmunoblastic T cell lymphoma, prognosis remains poor with an overall 5-year median survival of 32% 3.

It was initially described in 1974 by Frizzera et al as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).


Article information

rID: 35222
Synonyms or Alternate Spellings:
  • Angioimmunoblastic lymphadenopathy (AILD)
  • AILD
  • Angioimmunoblastic lymphadenopathy
  • Angioimmunoblastic lymphadenopathy with dysproteinaemia
  • Angioimmunoblastic lymphadenopathy with dysproteinemia
  • AITL
  • Angioimmunoblastic T-cell lymphoma (AITL)
  • Angioimmunoblastic T-cell lymphoma (AIL)
  • Immunoblastic lymphadenopathy–like T-cell lymphoma

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.